Display options
Cite
Wang X, Bao Z, Zhang X, et al. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(35):59901-59914doi: 10.18632/oncotarget.18316.
Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S. (2017). Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget, 8(35), 59901-59914. https://doi.org/10.18632/oncotarget.18316
Wang, Xiaohui, et al. "Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis." Oncotarget vol. 8,35 (2017): 59901-59914. doi: https://doi.org/10.18632/oncotarget.18316
Wang X, Bao Z, Zhang X, Li F, Lai T, Cao C, Chen Z, Li W, Shen H, Ying S. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017 May 31;8(35):59901-59914. doi: 10.18632/oncotarget.18316. eCollection 2017 Aug 29. PMID: 28938692; PMCID: PMC5601788.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 May 31;8(35):59901-59914. doi: 10.18632/oncotarget.18316. eCollection 2017 Aug 29.

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.

Oncotarget

Xiaohui Wang, Zhengqiang Bao, Xiaoju Zhang, Fei Li, Tianwen Lai, Chao Cao, Zhihua Chen, Wen Li, Huahao Shen, Songmin Ying

Affiliations

  1. Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China.
  2. Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China.
  3. Department of Respiratory Medicine, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
  4. State Key Laboratory of Respiratory Diseases, Guangzhou, China.

PMID: 28938692 PMCID: PMC5601788 DOI: 10.18632/oncotarget.18316

Abstract

BACKGROUND: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors.

METHODS: We searched PubMed, EMBASE, clinical trial registers, conference reports, and related reviews. Eligible RCTs that compared PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor patients were included. For each RCT, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were pooled for meta-analysis.

FINDINGS: Based on an analysis of 10 eligible RCTs, PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53 to 0.79,

INTERPRETATION: PD-1 inhibitors are more effective for improving the PFS, OS, and ORR of cancer patients with little toxicity, despite having little effect on increasing of the DCR.

Keywords: PD-1; PD-L1; cancer; nivolumab; pembrolizumab

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work.

References

  1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  2. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
  3. Trends Pharmacol Sci. 2015 Sep;36(9):587-95 - PubMed
  4. Immunol Lett. 2002 Oct 21;84(1):57-62 - PubMed
  5. J Immunother Cancer. 2015 Aug 18;3:36 - PubMed
  6. J Dtsch Dermatol Ges. 2016 Jan;14(1):28-37 - PubMed
  7. Curr Opin Immunol. 2012 Apr;24(2):207-12 - PubMed
  8. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  9. Onco Targets Ther. 2015 Aug 06;8:2045-51 - PubMed
  10. Internist (Berl). 2015 Aug;56(8):907-16; quiz 917 - PubMed
  11. N Engl J Med. 2015 May 21;372(21):2006-17 - PubMed
  12. Transl Lung Cancer Res. 2015 Oct;4(5):560-75 - PubMed
  13. Nat Rev Immunol. 2008 Jun;8(6):467-77 - PubMed
  14. N Engl J Med. 2015 Nov 5;373(19):1803-13 - PubMed
  15. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  16. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  17. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  18. J Adv Pract Oncol. 2014 Nov-Dec;5(6):418-31 - PubMed
  19. N Engl J Med. 2015 Jun 25;372(26):2521-32 - PubMed
  20. Lancet Oncol. 2015 Apr;16(4):375-84 - PubMed
  21. Lancet Oncol. 2014 Jan;15(1):69-77 - PubMed
  22. Lancet Oncol. 2015 Aug;16(8):908-18 - PubMed
  23. Exp Hematol Oncol. 2015 Dec 14;4:34 - PubMed
  24. Drugs. 2014 Oct;74(16):1973-81 - PubMed
  25. Br J Cancer. 2015 Apr 28;112(9):1421-7 - PubMed
  26. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  27. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  28. Oncotarget. 2015 Aug 14;6(23):19393-404 - PubMed
  29. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  30. N Engl J Med. 2015 Sep 24;373(13):1270-1 - PubMed
  31. Immunotherapy. 2015 ;7(7):777-92 - PubMed
  32. Clin Cancer Res. 2014 Oct 1;20(19):5064-74 - PubMed
  33. Curr Treat Options Oncol. 2015 May;16(5):20 - PubMed
  34. N Engl J Med. 2015 Jul 2;373(1):23-34 - PubMed
  35. Expert Rev Anticancer Ther. 2015;15(9):981-93 - PubMed
  36. Lancet. 2016 Apr 30;387(10030):1837-46 - PubMed
  37. J Immunol. 2002 Nov 15;169(10):5538-45 - PubMed
  38. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed

Publication Types